Scarica l'app Stockscreener
18.08
5.42%
0.93
Pre-mercato:
17.96
-0.12
-0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$17.15
Aprire:
$17.46
Volume 24 ore:
3.87M
Relative Volume:
1.18
Capitalizzazione di mercato:
$14.03B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-12.51
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
+12.19%
1M Prestazione:
-3.88%
6M Prestazione:
-0.55%
1 anno Prestazione:
-26.65%
Intervallo 1D:
$17.06
$18.15
Intervallo di 1 settimana:
$16.00
$18.19
Portata 52W:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.08 | 14.03B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply - simplywall.st
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
How (SMMT) Movements Inform Risk Allocation Models - Stock Traders Daily
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
SMMT Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Stock Analysis: Promising 91% Upside in the Biotech Sector - DirectorsTalk Interviews
Biopharmaceutical News: Summit Therapeutics Stock Plummets After Trial Analysis Misstep - geneonline.com
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies - timothysykes.com
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing - The Globe and Mail
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider LossesHas The Bull Case Changed? - simplywall.st
This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market - Yahoo Finance
TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating - Moomoo
Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results - MarketBeat
SMMT Plunges As Summit Therapeutics Stock Sheds Over 27% - timothysykes.com
Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen - MarketBeat
Summit Therapeutics Inc. Q1 2026 Financial Results: Forward-Looking Statements, Clinical Trial Updates, and Segment Reporting - Minichart
Summit Therapeutics Inc (SMMT) Stock Price, Quote, News & History - Benzinga
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Summit Therapeutics Shock Move Hits Nasdaq Futures - Kalkine Media
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch - Investor's Business Daily
U.S. Markets Closed Mixed Friday As Pershing Square Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics Shares Fall After 1Q Loss Widens - Moomoo
Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge - TechStock²
SMMT Maintains by Piper Sandler -- Price Target Lowered to $16.00 - GuruFocus
Summit Therapeutics (SMMT) Shares Drop 22% After Trial Update - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Summit Therapeutics (SMMT) Sees Significant Drop in Stock Price - GuruFocus
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Summit Therapeutics Stock Dips After Q1 Financial Report - Benzinga
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Summit Therapeutics (SMMT) slides 24.7% as investors digest Q1 loss and an interim trial update that didn’t deliver an early efficacy win - Quiver Quantitative
Summit Therapeutics stock falls after Q1 update (SMMT:NASDAQ) - Seeking Alpha
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - Yahoo Finance
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler - TipRanks
Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - BioSpace
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
Impressive Progress for SMMT with New Bispecific Antibody Develo - GuruFocus
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.97%
3.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):